

ALK<sup>+</sup> anaplastic large-cell lymphoma is clinically and  
both ALK+ ALCL and peripheral T-cell lymphoma, not o  
International Peripheral T-Cell Lymphoma Project

Blood

111, 5496-5504

DOI: 10.1182/blood-2008-01-134270

Citation Report

#	ARTICLE	IF	CITATIONS
1	Review article : Gastrointestinal damage following cardiopulmonary bypass. <i>Perfusion (United Kingdom)</i> , 2008, 23, 10-12.	0.5	12
2	Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 272-279.	0.9	29
3	Hematopoietic SCT for peripheral T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 773-781.	1.3	21
4	Pathobiology of Mature T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S168-S179.	1.4	9
5	Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. <i>Leukemia and Lymphoma</i> , 2008, 49, 2099-2107.	0.6	136
6	T-cell lymphoma "one name with a dozen faces". <i>Leukemia and Lymphoma</i> , 2008, 49, 2033-2034.	0.6	0
7	The Challenges of Epidemiologic Research in Non-Hodgkin Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2059.	3.8	14
8	Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 280-288.	0.9	38
9	Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. <i>Journal of Clinical Pathology</i> , 2008, 61, 1160-1167.	1.0	63
11	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009, 31, .	0.7	2
12	Frontline autologous stem cell transplantation for peripheral T-cell lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 255-260.	1.0	0
13	Analysis of Human T-Cell Lymphotropic Virus in CD25+ Anaplastic Large Cell Lymphoma in Children. <i>American Journal of Clinical Pathology</i> , 2009, 132, 28-33.	0.4	18
14	Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. <i>Haematologica</i> , 2009, 94, 897-900.	1.7	49
15	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. <i>Cancer Research</i> , 2009, 69, 8611-8619.	0.4	86
16	Applicability and Prognostic Value of the New TNM Classification System in 135 Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>Archives of Dermatology</i> , 2009, 145, 1399-404.	1.7	92
17	Aggressive non-Hodgkin's lymphoma. <i>Medicine</i> , 2009, 37, 202-207.	0.2	1
18	Anaplastic large cell lymphoma in leukemic phase: Extraordinarily high white blood cell count. <i>Pathology International</i> , 2009, 59, 345-353.	0.6	35
19	Lymphoma in Adolescents and Young Adults. <i>Seminars in Oncology</i> , 2009, 36, 381-418.	0.8	73

#	ARTICLE	IF	CITATIONS
20	Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. <i>Hematological Oncology</i> , 2009, 27, 161-170.	0.8	61
21	Adrenal extranodal NK/T-cell lymphoma diagnosed by fine-needle aspiration and cerebrospinal fluid cytology and immunophenotyping: A case report. <i>Diagnostic Cytopathology</i> , 2009, 37, 686-695.	0.5	23
22	Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task. <i>International Journal of Hematology</i> , 2009, 90, 226-229.	0.7	15
23	Diagnostische Schritte und Therapieoptionen bei peripheren T-Zell-Neoplasien. <i>Wiener Klinische Wochenschrift Education</i> , 2009, 4, 165-176.	0.0	0
24	Update on the World Health Organization classification of peripheral T-cell lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 227-235.	1.2	18
25	Mature T-cell malignancies: a diagnostic and therapeutic challenge. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 134-141.	0.3	0
26	Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. <i>Journal of Hematopathology</i> , 2009, 2, 237-244.	0.2	48
27	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. <i>Journal of Molecular Medicine</i> , 2009, 87, 669-677.	1.7	10
28	Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. <i>Leukemia</i> , 2009, 23, 574-580.	3.3	195
29	The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. <i>Leukemia</i> , 2009, 23, 2290-2299.	3.3	38
30	Primary Cutaneous CD30 Positive Anaplastic Large Cell Lymphoma in an Adolescent. <i>Pediatric Dermatology</i> , 2009, 26, 721-724.	0.5	12
31	Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 181-198.	2.0	20
32	Molecular classification of T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 125-143.	2.0	67
33	Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 331-356.	1.1	206
34	Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125.	2.0	49
35	Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 106-113.	0.8	380
36	The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 523-531.	0.9	481
37	Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1093-1101.	5.1	121

#	ARTICLE	IF	CITATIONS
38	The spectrum of peripheral T-cell lymphomas. <i>Current Opinion in Hematology</i> , 2009, 16, 292-298.	1.2	17
40	Anaplastic lymphoma kinase: signalling in development and disease. <i>Biochemical Journal</i> , 2009, 420, 345-361.	1.7	375
41	ALK <sup>+</sup> anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK <sup>+</sup> ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Yearbook of Pathology and Laboratory Medicine</i> , 2009, 2009, 190-191.	0.0	0
42	Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2009, 113, 3931-3937.	0.6	656
43	Pagetoid Reticulosis After Radiotherapy of Primary Cutaneous Anaplastic Large-Cell Lymphoma. <i>American Journal of Dermatopathology</i> , 2010, 32, 79-82.	0.3	8
44	Secondary ALK Negative Anaplastic Large Cell Lymphoma in a Patient With Lymphomatoid Papulosis of 40 Years Duration. <i>American Journal of Dermatopathology</i> , 2010, 32, 708-712.	0.3	6
46	Non-Hodgkin <sup>+</sup> Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
47	Prophylaxis of invasive fungal diseases in patients with hematologic disorders. <i>Haematologica</i> , 2010, 95, 1630-1632.	1.7	8
48	CD30+ lymphoproliferative disorders. <i>Haematologica</i> , 2010, 95, 1627-1630.	1.7	33
49	T- and NK-cell lymphoma update. <i>Diagnostic Histopathology</i> , 2010, 16, 99-110.	0.2	2
50	Rare Pediatric Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 163-168.	1.2	16
51	Prognostic Markers in Peripheral T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 222-228.	1.2	30
52	Diffuse pulmonary infiltration by anaplastic lymphoma kinase negative anaplastic large cell lymphoma: A case report and literature review. <i>Respiratory Medicine CME</i> , 2010, 3, 260-262.	0.1	3
53	THP <sup>+</sup> COP regimen for the treatment of peripheral T <sup>+</sup> cell lymphoma and adult T <sup>+</sup> cell leukemia/lymphoma: a multicenter phase II study. <i>European Journal of Haematology</i> , 2010, 84, 391-397.	1.1	19
54	ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as <sup>+</sup> leukemic phase <sup>+</sup> . <i>Leukemia Research</i> , 2010, 34, 475-482.	0.4	22
55	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T <sup>+</sup> cell and natural killer <sup>+</sup> cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	1.2	44
56	Pathobiology of Anaplastic Large Cell Lymphoma. <i>Advances in Hematology</i> , 2010, 2010, 1-10.	0.6	17
58	Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. <i>Journal of Clinical Oncology</i> , 2010, 28, 1583-1590.	0.8	152

#	ARTICLE	IF	CITATIONS
59	Cardiac Presentation of Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e314-e316.	0.8	5
60	Infant Anaplastic Large Cell Lymphoma with Hemophagocytic Syndrome. <i>Pediatric and Developmental Pathology</i> , 2010, 13, 72-76.	0.5	7
61	PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. <i>Modern Pathology</i> , 2010, 23, 593-602.	2.9	69
62	Diagnosis of Nodal Peripheral T-Cell Lymphomas. <i>Surgical Pathology Clinics</i> , 2010, 3, 955-988.	0.7	1
64	Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. <i>Leukemia and Lymphoma</i> , 2010, 51, 1968-2005.	0.6	53
65	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
66	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i> , 2010, 116, 3418-3425.	0.6	482
67	Clinical Management of Non-cutaneous T-cell and NK-cell Malignancies. , 2010, , 413-426.		0
68	Human immunodeficiency virus-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 430-438.	0.6	35
69	Brentuximab vedotin: delivering an antimetabolic drug to activated lymphoma cells. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 99-105.	1.9	35
70	Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4669-4676.	0.8	142
71	Lymphoma Cytogenetics. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 725-761.	0.7	12
72	Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 203-209.	3.3	10
73	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	0.6	1,681
74	High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1481-1489.	2.0	31
75	Lymphoma classification: the quiet after the storm. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 113-123.	1.0	20
76	A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma. <i>Pathology Research and Practice</i> , 2011, 207, 522-526.	1.0	8
77	Improving therapy for patients with aggressive lymphoma. <i>Transfusion and Apheresis Science</i> , 2011, 44, 179-182.	0.5	0

#	ARTICLE	IF	CITATIONS
78	Brentuximab Vedotin (SGN-35). <i>Clinical Cancer Research</i> , 2011, 17, 6428-6436.	3.2	333
79	Anaplastic large-cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 190-201.	1.0	33
80	Perils and Pitfalls Regarding Differential Diagnosis and Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma. <i>Scientific World Journal, The</i> , 2011, 11, 1048-1055.	0.8	13
81	An update on the management of peripheral T-cell lymphoma and emerging treatment options. <i>Journal of Blood Medicine</i> , 2011, 2, 119.	0.7	5
82	Tricky and Terrible T-Cell Tumors: These are Thrilling Times for Testing: Molecular Pathology of Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 336-343.	0.9	12
83	Anaplastic Large T-Cell Lymphoma and Breast Implants. <i>Plastic and Reconstructive Surgery</i> , 2011, 128, 651-661.	0.7	78
84	Diagnosis and Management of Seroma following Breast Augmentation: An Update. <i>Plastic and Reconstructive Surgery</i> , 2011, 128, 17-25.	0.7	13
85	Anaplastic Large Cell Lymphoma and Breast Implants: A Systematic Review. <i>Plastic and Reconstructive Surgery</i> , 2011, 127, 2141-2150.	0.7	167
86	Peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 6756-6767.	0.6	278
87	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. <i>Blood</i> , 2011, 117, 915-919.	0.6	279
88	Malignant hematologic diseases in adolescents and young adults. <i>Blood</i> , 2011, 117, 5803-5815.	0.6	99
91	Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell) <a href="#">Tj ETQq1 1.0.784314 rgBT / 1.2 1038</a>		
92	Anaplastic large cell lymphoma with paraneoplastic leukocytosis: a clinicopathological analysis of five cases. <i>Apmis</i> , 2011, 119, 794-801.	0.9	4
93	A case of systemic anaplastic large cell lymphoma with "Hodgkin-like" appearance and skin involvement mimicking lymphomatoid papulosis. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 38-42.	0.7	4
94	Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. <i>Leukemia</i> , 2011, 25, 153-160.	3.3	86
95	Pathology and biology of peripheral T-cell lymphomas. <i>Histopathology</i> , 2011, 58, 49-68.	1.6	50
96	ALK-negative systemic intravascular anaplastic large cell lymphoma presenting in the skin. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 216-220.	0.7	26
97	Treatment algorithms for mature T-cell and natural killer-cell neoplasms. <i>Future Oncology</i> , 2011, 7, 1101-1112.	1.1	9

#	ARTICLE	IF	CITATIONS
99	Anaplastic large cell lymphoma (monomorphic post-transplant lymphoproliferative disorder) presenting in gallbladder. <i>Journal of Hematopathology</i> , 2011, 4, 17-20.	0.2	1
100	Update: Peripheral T-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 222-230.	1.2	11
101	Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study. <i>American Journal of Hematology</i> , 2011, 86, 256-261.	2.0	42
102	Functions and Uses of Immunohistochemical Stains in Cutaneous Infiltrates of Hematopoietic Origin: A Review for the Practicing Dermatologist. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 65-83.	0.6	4
103	Anaplastic lymphoma kinase in human cancer. <i>Journal of Molecular Endocrinology</i> , 2011, 47, R11-R23.	1.1	116
104	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1127-1136.	1.9	27
105	ALK-negative anaplastic large cell lymphoma mimicking a soft tissue sarcoma. <i>Journal of Cytology</i> , 2011, 28, 230.	0.2	15
106	Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 161-173.	1.1	10
107	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. <i>Modern Pathology</i> , 2011, 24, 596-605.	2.9	178
108	An algorithmic approach to the diagnosis of NK and T cell lymphomas. <i>Pathology</i> , 2011, 43, 673-681.	0.3	5
109	Brentuximab vedotin for the treatment of CD30 <sup>+</sup> lymphomas. <i>Immunotherapy</i> , 2011, 3, 475-485.	1.0	37
110	Pathobiology of ALK-negative anaplastic large cell lymphoma. <i>Mental Illness</i> , 2011, 3, 5.	0.8	10
111	Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 2012, , 517-527.		1
112	Acute Leukemic Manifestation of Recurrent Anaplastic Large-Cell Lymphoma 20 Years After Autologous Bone Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, e34-e36.	0.8	4
113	Anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma- Is it a new variant?. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2012, 78, 354.	0.2	8
114	Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1,0,784314,rgBT /Ove 1.0 41	1.0	41
115	Risk of lymphoma in women with breast implants. <i>European Journal of Cancer Prevention</i> , 2012, 21, 274-280.	0.6	30
116	Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 209-225.	1.1	90

#	ARTICLE	IF	CITATIONS
117	Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1124-1129.	0.6	41
118	Brentuximab vedotin. <i>MAbs</i> , 2012, 4, 458-465.	2.6	116
119	Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 3939-3946.	0.8	162
120	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. <i>Journal of Clinical Oncology</i> , 2012, 30, 3093-3099.	0.8	490
121	Brentuximab vedotin in anaplastic large cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 633-639.	1.4	9
122	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. <i>Blood</i> , 2012, 120, 2280-2289.	0.6	208
123	ALK signaling and target therapy in anaplastic large cell lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 41.	1.3	39
124	Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 90-97.	0.5	130
125	Leukemic Presentation of ALK-negative Anaplastic Large Cell Lymphoma in a Patient with Myelodysplastic Syndrome. <i>Internal Medicine</i> , 2012, 51, 199-203.	0.3	7
126	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2012, 120, 1274-1281.	0.6	101
127	Targeting CD30 in Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 285-291.	1.2	7
128	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	0.8	890
129	Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. <i>Annals of Pharmacotherapy</i> , 2012, 46, 377-383.	0.9	35
130	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2012, 380, 848-857.	6.3	522
132	RNASSET2 " An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. <i>Journal of Proteomics</i> , 2012, 75, 5279-5292.	1.2	9
133	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.	3.2	204
134	Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. <i>Modern Pathology</i> , 2012, 25, 983-992.	2.9	54
135	Brentuximab vedotin in systemic T-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 623-632.	1.4	20



#	ARTICLE	IF	CITATIONS
136	Emerging Treatment Options for Advanced-Stage Mycosis Fungoides. <i>Journal of Clinical Oncology</i> , 2012, 30, 4064-4070.	0.8	2
137	Anaplastic Large Cell Lymphoma: An Unusual Presentation in a 7-year-Old Girl. <i>Pediatric Dermatology</i> , 2012, 29, 498-503.	0.5	10
138	Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. <i>Blood</i> , 2012, 120, 3997-4005.	0.6	68
139	New biomarkers in T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 13-28.	0.7	19
140	Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 205-216.	1.9	64
141	Case report: a unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle. <i>Diagnostic Pathology</i> , 2012, 7, 38.	0.9	9
142	Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report. <i>Diagnostic Pathology</i> , 2012, 7, 79.	0.9	11
143	Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. <i>Journal of Hematology and Oncology</i> , 2012, 5, 38.	6.9	13
144	<sc>HIV</sc>-associated primary cutaneous anaplastic large cell lymphoma: a clinicopathological subset with more aggressive behavior? Case report and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 1100-1109.	0.7	15
145	Hodgkin and Non-Hodgkin Lymphomas. , 2012, , 605-617.		0
146	Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 106-112.	0.2	13
147	Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 280-283.	0.2	30
148	Anaplastic large cell lymphoma, ALK-positive. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 293-302.	2.0	98
149	Anaplastic large cell lymphoma as a cause of rapidly appearing subcutaneous nodules in an HIV-infected patient. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2012, 30, 581-582.	0.3	0
150	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	1.7	28
151	Treating T-cell lymphoma: is there a light at the end of the tunnel?. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 174-177.	0.3	0
152	Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. <i>Leukemia</i> , 2012, 26, 188-190.	3.3	17
153	Novel treatment avenues for peripheral T-cell lymphomas. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1149-1163.	2.5	4

#	ARTICLE	IF	CITATIONS
154	ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol 3-kinase/akt activity with retained but inactivated PTEN—A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012, 59, 440-447.	0.8	6
155	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. <i>Leukemia</i> , 2012, 26, 1908-1975.	3.3	738
156	The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 511-519.	2.0	70
157	The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project. <i>American Journal of Hematology</i> , 2012, 87, 790-794.	2.0	38
158	Peripheral T cell and natural killer (NK)-T cell lymphomas: a clinicopathological study from a single Australian centre. <i>Histopathology</i> , 2012, 61, 212-223.	1.6	5
159	Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 387-395.	1.1	3
160	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 371-379.	2.0	74
162	Anaplastic large cell lymphoma, ALK-negative. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 206-215.	2.0	129
163	ALK-Positive Anaplastic Large Cell Lymphoma. , 2013, , 307-314.		1
165	Actualit�s th�rapeutiques dans les lymphomes. , 2013, , .		0
166	Non-Hodgkin Lymphoma. , 2013, , .		1
167	T-Cell Lymphomas. , 2013, , .		1
168	Atlas of Lymph Node Pathology. , 2013, , .		8
169	Diagnostic Pathology of Pleuropulmonary Neoplasia. , 2013, , .		8
170	Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data?. <i>Current Treatment Options in Oncology</i> , 2013, 14, 212-223.	1.3	20
171	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 196-210.	1.2	66
172	Successful treatment of small cell variant anaplastic large cell lymphoma with allogeneic peripheral blood stem cell transplantation, and review of the literature. <i>International Journal of Hematology</i> , 2013, 97, 139-143.	0.7	5
173	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. <i>Annals of Hematology</i> , 2013, 92, 1041-1048.	0.8	15

#	ARTICLE	IF	CITATIONS
174	Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. <i>Annals of Hematology</i> , 2013, 92, 925-933.	0.8	9
175	Approaches for First-Line Therapy of Peripheral T-Cell Lymphoma. , 2013, , 217-228.		0
176	International analysis of the frequency and outcomes of NK/T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 23-32.	0.7	63
177	Pathobiology of T-cell and NK-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 75-87.	0.7	16
178	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013, 122, 2683-2693.	0.6	98
179	Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. <i>Modern Pathology</i> , 2013, 26, S71-S87.	2.9	106
180	The aggressive peripheral Tâ€cell lymphomas: 2013. <i>American Journal of Hematology</i> , 2013, 88, 910-918.	2.0	21
182	Two cases of CD30+, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with oral manifestations. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 115, e41-e47.	0.2	8
183	Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 275-277.	0.3	0
184	Novel <i>TRAF1â€ALK</i> fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1097-1102.	1.5	51
185	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. <i>Nature Reviews Cancer</i> , 2013, 13, 685-700.	12.8	538
186	Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma with MUM1 expression. <i>Esophagus</i> , 2013, 10, 51-54.	1.0	2
187	Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 361-373.	1.0	6
188	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 857-877.	0.6	268
189	Non-Hodgkin lymphoma: the clinician's perspectiveâ€a view from the receiving end. <i>Modern Pathology</i> , 2013, 26, S111-S118.	2.9	13
190	Brentuximab Vedotin: A <sc>CD</sc>30â€Directed Antibodyâ€Cytotoxic Drug Conjugate. <i>Pharmacotherapy</i> , 2013, 33, 93-104.	1.2	51
191	NK/T-cell lymphomas in children. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 33-41.	0.7	6
192	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. <i>Cancer Genetics</i> , 2013, 206, 357-373.	0.2	51

#	ARTICLE	IF	CITATIONS
193	Non-Hodgkin's lymphoma. <i>Medicine</i> , 2013, 41, 282-289.	0.2	14
194	Brentuximab Vedotin. <i>Clinical Cancer Research</i> , 2013, 19, 22-27.	3.2	134
195	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
196	Pathology of Non-Hodgkin's and Hodgkin's Lymphomas. , 2013, , 867-918.		0
197	Immunology of the Lymphomas. , 2013, , 919-943.		0
198	The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas: characteristic features and diagnostic dilemmas. <i>Human Pathology</i> , 2013, 44, 451-471.	1.1	10
199	Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 493-495.	0.2	14
200	microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. <i>Blood</i> , 2013, 122, 2083-2092.	0.6	84
202	Differential expression of aurora-A kinase in T-cell lymphomas. <i>Modern Pathology</i> , 2013, 26, 640-647.	2.9	25
203	CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. <i>Haematologica</i> , 2013, 98, 1250-1258.	1.7	56
204	Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. <i>Bone Marrow Transplantation</i> , 2013, 48, 1484-1485.	1.3	9
205	Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders with Biallelic Rearrangements of DUSP22. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1680-1682.	0.3	17
206	Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading As Metastatic Carcinoma of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2013, 31, e443-e445.	0.8	19
207	Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data. <i>Clinical Investigation</i> , 2013, 3, 665-679.	0.0	1
208	Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis. <i>Current Opinion in Hematology</i> , 2013, 20, 374-381.	1.2	17
209	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	0.8	206
210	Anaplastic Lymphoma Kinase (ALK1) Immunohistochemistry in Diagnostic Dermatopathology; An Update. <i>American Journal of Dermatopathology</i> , 2013, 35, 403-411.	0.3	3
211	Primary Cutaneous Anaplastic Large-cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 526-529.	0.6	7

#	ARTICLE	IF	CITATIONS
212	Differentiating pulmonary cavities. <i>European Respiratory Review</i> , 2013, 22, 191-192.	3.0	1
213	Les lymphomes cutanÃ©s. , 2013, , .		0
214	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	0.8	129
215	PTCL Therapies. <i>American Journal of Therapeutics</i> , 2013, 20, 524-533.	0.5	1
216	Anaplastic large cell lymphoma: A single institution experience from India. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 649.	0.3	9
217	Brentuximab vedotin: An anti-CD30 antibodyâ€“drug conjugate. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 589-597.	0.5	33
218	Favorable outcome with doxorubicinâ€“based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic largeâ€“cell lymphoma. <i>European Journal of Haematology</i> , 2013, 90, 195-201.	1.1	18
219	Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. <i>Journal of Clinical Oncology</i> , 2013, 31, 1970-1976.	0.8	335
220	Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. <i>Blood Cancer Journal</i> , 2013, 3, e111-e111.	2.8	19
224	Anaplastic Large Cell Lymphoma Mimicking Fibrosing Mediastinitis. <i>Internal Medicine</i> , 2013, 52, 2645-2651.	0.3	6
225	Recurrent ALK-Negative Anaplastic Large T-Cell Lymphoma Presenting as Necrotizing Vasculitis. <i>American Journal of Dermatopathology</i> , 2013, 35, 512-516.	0.3	13
226	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. , 2013, , .		2
227	Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course. <i>American Journal of Surgical Pathology</i> , 2013, 37, 617-623.	2.1	36
228	Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children. <i>Oncology Letters</i> , 2013, 5, 515-520.	0.8	5
230	Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. <i>OncoTargets and Therapy</i> , 2013, 7, 45.	1.0	15
231	Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease. <i>Canadian Journal of Plastic Surgery</i> , 2013, 21, 95-98.	0.4	21
232	ALK-driven tumors and targeted therapy: focus on crizotinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 87.	0.4	14
233	Pathobiology of Peripheral T-Cell Lymphomas. , 2014, , 1732-1748.		1

#	ARTICLE	IF	CITATIONS
234	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1123.	1.0	7
235	ALK-positive cancer: still a growing entity. <i>Future Oncology</i> , 2014, 10, 305-321.	1.1	11
236	Anaplastic large cell lymphoma presenting as a cerebellar mass. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 157-161.	0.6	7
237	Emerging drugs for T-cell lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 201-213.	1.0	4
238	The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 711-718.	1.9	3
239	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, , 69.	1.2	2
240	Automatic lymphoma classification with sentence subgraph mining from pathology reports. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 824-832.	2.2	54
241	Multiple Pulmonary Nodules and Unexplained Fever: When the Pulmonologist Fails. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 309-311.	1.0	0
242	The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 727-729.	0.6	8
243	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Review of a Distinct Clinicopathologic Entity. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 842-846.	1.2	69
244	Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. <i>Cancer Science</i> , 2014, 105, 840-846.	1.7	48
245	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. <i>European Journal of Haematology</i> , 2014, 93, 455-468.	1.1	38
246	Anaplastic large cell lymphoma (ALCL) and breast implants: Breaking down the evidence. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 762, 123-132.	2.4	52
247	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014, 25, 2339-2350.	0.6	15
248	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	0.6	126
249	The importance of Notch signaling in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 639-644.	0.6	17
250	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291.	0.7	5
251	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 768-775.	2.1	44

#	ARTICLE	IF	CITATIONS
252	Molecular Diagnostics of T-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass ), 2014, 20, 48-60.	1.0	4
253	Intracellular TCR-signaling Pathway. American Journal of Surgical Pathology, 2014, 38, 1349-1359.	2.1	19
254	High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. Histopathology, 2014, 65, 490-500.	1.6	42
255	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 66-75.	0.9	52
256	Aggressive Subcutaneous Panniculitis-Like CD30+ Peripheral T-Cell Lymphoma with Diffuse EBER Expression. Case Reports in Hematology, 2014, 2014, 1-4.	0.3	3
257	Extranodal anaplastic large cell lymphoma mimicking sarcoma: A report of an interesting case. International Journal of Applied & Basic Medical Research, 2014, 4, 50.	0.2	2
259	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 <sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study. Journal of Clinical Oncology, 2014, 32, 3137-3143.	0.8	153
260	Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis. American Journal of Surgical Pathology, 2014, 38, 1203-1211.	2.1	42
261	Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma. Seminars in Hematology, 2014, 51, 17-24.	1.8	14
262	Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. Seminars in Hematology, 2014, 51, 73-86.	1.8	10
263	Leukemic Phase of ALK+ Anaplastic Large-Cell Lymphoma, Small-Cell Variant: Clinicopathologic Pitfalls of a Rare Entity. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e123-e126.	0.2	4
264	CD30 in Systemic Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 341-355.	0.7	21
265	Pathology of Peripheral T-Cell Lymphomas: Where Do We Stand?. Seminars in Hematology, 2014, 51, 5-16.	1.8	48
266	Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with extranodal involvement of the thigh muscle: a case report. Journal of Medical Case Reports, 2014, 8, 9.	0.4	6
267	Pediatric Hematology-Oncology in Countries with Limited Resources. , 2014, , .		7
268	Decision Tools for Radiation Oncology. Medical Radiology, 2014, , .	0.0	2
269	Peripheral T cell lymphoma in Asia. International Journal of Hematology, 2014, 99, 227-239.	0.7	53
270	Molecular genetics of peripheral T-cell lymphomas. International Journal of Hematology, 2014, 99, 219-226.	0.7	27

#	ARTICLE	IF	CITATIONS
271	Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 589-598.	1.2	30
272	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt378.	3.0	207
273	Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVI <sup>th</sup> meeting of the European Association for Haematopathology and the Society for Hematopathology. <i>Histopathology</i> , 2014, 64, 171-199.	1.6	144
275	Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 5240-5254.	3.2	40
276	Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs. <i>Molecular Cancer</i> , 2014, 13, 199.	7.9	15
277	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
278	CD30 as a Therapeutic Target for Lymphoma. <i>BioDrugs</i> , 2014, 28, 181-209.	2.2	32
279	A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1345-1354.	2.9	28
280	The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies. <i>Seminars in Hematology</i> , 2014, 51, 25-34.	1.8	27
281	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	0.6	48
282	Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 465-471.	2.3	24
283	Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 323-326.	2.3	22
284	Past, present and future treatment strategies in peripheral T-cell lymphomas. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 299-311.	0.7	0
285	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	0.6	435
286	How I treat the peripheral T-cell lymphomas. <i>Blood</i> , 2014, 123, 2636-2644.	0.6	132
287	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	0.6	280
288	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
289	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. <i>Blood</i> , 2014, 124, 1570-1577.	0.6	309



#	ARTICLE	IF	CITATIONS
290	Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. <i>Blood</i> , 2014, 124, 2983-2986.	0.6	89
291	A case of anaplastic large cell lymphoma of skeletal muscle. <i>Journal of Dermatology</i> , 2014, 41, 999-1002.	0.6	4
292	Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 550-558.	0.9	10
293	X. Challenges and future directions in peripheral T-cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 56-61.	0.8	2
294	The aggressive peripheral T-cell lymphomas: 2015. <i>American Journal of Hematology</i> , 2015, 90, 665-673.	2.0	22
295	Correlation of BAG-3 and Heat Shock Protein 70 with CD30 expression in T-cell Lymphomas. <i>Scientific Reports</i> , 2014, 4, 3952.	1.6	3
296	Anaplastic large cell lymphoma with primary involvement of the skeletal muscle: A case report. <i>Oncology Letters</i> , 2015, 9, 2815-2818.	0.8	4
297	Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. <i>Blood</i> , 2015, 126, 36-41.	0.6	44
298	Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. <i>Blood</i> , 2015, 126, 1257-1258.	0.6	40
300	Expression of the Chemokine Receptor Gene, CCR8, is Associated With DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 580-589.	0.6	12
301	Primary CNS T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1719-1729.	2.1	53
302	Anaplastic large cell lymphoma involving the urinary bladder: A case report and review of the literature. <i>Diagnostic Cytopathology</i> , 2015, 43, 60-65.	0.5	8
303	Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma with involvement of the urinary bladder: a case report and review of literature. <i>OncoTargets and Therapy</i> , 2015, 8, 1143.	1.0	1
304	ALK-positive anaplastic large cell lymphoma an evolving story. <i>Frontiers in Bioscience - Scholar</i> , 2015, 7, 248-259.	0.8	5
305	PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211159.	0.2	7
306	Anaplastic Large-Cell Lymphoma in Aids. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 378-380.	0.2	1
307	Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma with Colon Involvement. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 345-346.	0.8	1
308	A Primary Systemic ALCL Present Initially as Cutaneous Localized Skin Lesions. <i>American Journal of Dermatopathology</i> , 2015, 37, e12-e14.	0.3	4

#	ARTICLE	IF	CITATIONS
309	CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1376-1384.	1.9	153
310	Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2227-2235.	3.2	236
311	Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. <i>Hematological Oncology</i> , 2015, 33, 120-128.	0.8	15
313	Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2015, 20, 1084-1091.	1.9	55
314	Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 2015, 168, 771-783.	1.2	43
315	Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule. <i>International Journal of Surgical Pathology</i> , 2015, 23, 333-335.	0.4	8
316	Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 855-859.	2.0	36
317	The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. <i>Current Medical Research and Opinion</i> , 2015, 31, 537-545.	0.9	8
318	Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins™ Lymphoma in First Remission. <i>Current Treatment Options in Oncology</i> , 2015, 16, 34.	1.3	5
319	Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. <i>Leukemia and Lymphoma</i> , 2015, 56, 1778-1786.	0.6	48
320	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Cancer Treatment Communications</i> , 2015, 4, S1-S11.	0.4	1
321	Gene Expression Profiling in Non-Hodgkin Lymphomas. <i>Cancer Treatment and Research</i> , 2015, 165, 97-123.	0.2	3
322	Atlas of Cutaneous Lymphomas. , 2015, , .		4
323	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015, 29, 1390-1401.	3.3	42
324	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
325	Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. <i>BMC Cancer</i> , 2015, 15, 11.	1.1	9
326	Pathology of T-Cell Lymphomas: Diagnosis and Biomarker Discovery. <i>Cancer Treatment and Research</i> , 2015, 165, 51-95.	0.2	4
327	Current Management of Peripheral T-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2015, 165, 289-303.	0.2	7

#	ARTICLE	IF	CITATIONS
328	The biology and management of systemic anaplastic large cell lymphoma. <i>Blood</i> , 2015, 126, 17-25.	0.6	157
329	Anaplastic Large Cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2015, 22, 29-49.	2.4	102
330	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	2.1	49
331	Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors. <i>Blood Cancer Journal</i> , 2015, 5, e332-e332.	2.8	3
332	Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 1151-1153.	0.6	11
333	Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. <i>British Journal of Haematology</i> , 2015, 168, 708-718.	1.2	29
334	The ALK Receptor Family. , 2015, , 1-51.		0
335	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v108-v115.	0.6	172
336	Coming of Age. <i>Clinics in Plastic Surgery</i> , 2015, 42, 605-613.	0.7	79
337	Mature T-cell lymphomas. <i>Diagnostic Histopathology</i> , 2015, 21, 408-420.	0.2	2
338	Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. <i>Immunological Reviews</i> , 2015, 263, 124-159.	2.8	30
339	Pediatric Lymphomas and Histiocytic Disorders of Childhood. <i>Pediatric Clinics of North America</i> , 2015, 62, 139-165.	0.9	77
340	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 703-710.	0.6	29
341	ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. <i>Clinical Neuroradiology</i> , 2015, 25, 177-179.	1.0	4
342	CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy. <i>Annals of Dermatology</i> , 2016, 28, 371.	0.3	0
343	Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217317.	0.2	7
344	Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 176.	0.4	4
346	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2016, 40, 36-43.	2.1	103

#	ARTICLE	IF	CITATIONS
347	Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. <i>American Journal of Hematology</i> , 2016, 91, 672-676.	2.0	27
348	Anaplastic large cell lymphoma in paediatric and young adult patients. <i>British Journal of Haematology</i> , 2016, 173, 560-572.	1.2	82
349	Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. <i>British Journal of Haematology</i> , 2016, 173, 573-581.	1.2	23
350	Adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 637-650.	1.2	30
351	Indurated papules and plaques on left hemithorax: a clinicopathologic challenge. <i>International Journal of Dermatology</i> , 2016, 55, e123-5.	0.5	0
352	Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. <i>Haematologica</i> , 2016, 101, e103-e106.	1.7	30
353	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e27-e29.	1.7	24
354	T-cell Lymphomas. <i>Surgical Pathology Clinics</i> , 2016, 9, 131-141.	0.7	12
355	Cutaneous manifestations and management of hematologic neoplasms. <i>Seminars in Oncology</i> , 2016, 43, 370-383.	0.8	20
356	PET/CT in Lymphomas. , 2016, , .		4
357	Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening?. <i>Pathogenesis</i> , 2016, 3, 9-18.	0.8	12
358	Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. <i>Diagnostic Pathology</i> , 2016, 11, 83.	0.9	9
360	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. <i>Oncologist</i> , 2016, 21, 1436-1441.	1.9	15
361	Primary cutaneous CD30 <sup>+</sup> lymphoproliferative disorders. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 767-782.	0.4	12
362	First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2016, 6, e452-e452.	2.8	58
363	A Snowy White Stomach, Caused by Primary Gastric Anaplastic Large-Cell Lymphoma. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, A21.	2.4	0
364	Primär kutane CD30 <sup>+</sup> lymphoproliferative Erkrankungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 767-784.	0.4	8
365	ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. <i>Annals of Hematology</i> , 2016, 95, 1725-1726.	0.8	15

#	ARTICLE	IF	CITATIONS
366	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e387-e390.	1.7	124
367	No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course. <i>Blood</i> , 2016, 128, 141-143.	0.6	12
368	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016, 127, 221-232.	0.6	97
370	15. Anaplastic large cell lymphoma. , 2016, , 285-310.		0
371	Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2016, 9, 22.	6.9	38
372	Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. <i>Annals of Hematology</i> , 2016, 95, 1271-1280.	0.8	8
373	Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). <i>Annals of Hematology</i> , 2016, 95, 619-624.	0.8	4
374	An update of ALK inhibitors in human clinical trials. <i>Future Oncology</i> , 2016, 12, 71-81.	1.1	9
375	Cutaneous anaplastic large-cell lymphoma (ALCL): A comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1135-1143.	0.6	18
376	The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2016, 21, 102-109.	1.9	34
377	Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. <i>Expert Review of Hematology</i> , 2016, 9, 137-150.	1.0	20
378	Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 546-552.	3.2	61
379	Spontaneous regression of a systemic ALK (+) anaplastic large cell lymphoma carrying ALK gene rearrangement that developed after PPD tuberculin skin test. <i>Leukemia and Lymphoma</i> , 2016, 57, 480-482.	0.6	1
380	CHOP or THPâ€COP regimens in the treatment of newly diagnosed peripheral Tâ€cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. <i>Hematological Oncology</i> , 2017, 35, 163-171.	0.8	7
381	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2017, 390, 298-310.	6.3	615
382	Pediatric case of anaplastic lymphoma kinaseâ€positive anaplastic large cell lymphoma forming a solitary skin tumor on the forearm. <i>Journal of Dermatology</i> , 2017, 44, 465-467.	0.6	2
383	The addition of etoposide to <sc>CHOP</sc> is associated with improved outcome in <sc>ALK</sc>+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2017, 178, 739-746.	1.2	28
384	The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. <i>Acta Clinica Belgica</i> , 2017, 72, 454-460.	0.5	3

#	ARTICLE	IF	CITATIONS
385	PAX-5 Positivity in Anaplastic Lymphoma Kinase- Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. International Journal of Surgical Pathology, 2017, 25, 333-338.	0.4	10
386	2016 WHO Classification update- What's new in lymphoid neoplasms. International Journal of Laboratory Hematology, 2017, 39, 14-22.	0.7	16
387	Management of Lymphomas: A Case-Based Approach. , 2017, , .		0
388	Cancer Cytogenetics. Methods in Molecular Biology, 2017, , .	0.4	4
389	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer, 2017, 123, 1174-1183.	2.0	51
390	Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Methods in Molecular Biology, 2017, 1541, 279-293.	0.4	12
391	The aggressive peripheral T-cell lymphomas: 2017. American Journal of Hematology, 2017, 92, 706-715.	2.0	81
392	ALK Expression is a Rare Finding in Mycosis Fungoides. American Journal of Dermatopathology, 2017, 39, 342-343.	0.3	4
393	Skin involvement as the first symptom of rapidly progressive ALK-positive systemic anaplastic large cell lymphoma. Clinical and Experimental Dermatology, 2017, 42, 539-542.	0.6	3
394	Treatment of Peripheral T-Cell Lymphoma in Community Settings. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 354-361.	0.2	5
396	Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 201-206.	0.2	9
397	Peripheral T-Cell Lymphoma, Not Otherwise Specified. Hematology/Oncology Clinics of North America, 2017, 31, 189-207.	0.9	15
398	CD30 + Lymphoproliferative Disorders of the Skin. Hematology/Oncology Clinics of North America, 2017, 31, 317-334.	0.9	31
399	Management of Anaplastic Large Cell Lymphoma. Hematology/Oncology Clinics of North America, 2017, 31, 209-222.	0.9	20
400	Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas. Hematology/Oncology Clinics of North America, 2017, 31, 335-357.	0.9	12
401	Primary cutaneous anaplastic large cell lymphoma. Journal of Cutaneous Pathology, 2017, 44, 570-577.	0.7	47
402	Genetic Landscape and Classification of Peripheral T Cell Lymphomas. Current Oncology Reports, 2017, 19, 28.	1.8	43
403	Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Review of Hematology, 2017, 10, 29-37.	1.0	43

#	ARTICLE	IF	CITATIONS
404	Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral Tâ€cell lymphoma. <i>Cancer Medicine</i> , 2017, 6, 36-44.	1.3	17
405	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.	0.6	176
406	Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. <i>Future Oncology</i> , 2017, 13, 2405-2411.	1.1	14
407	Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. <i>Blood Cancer Journal</i> , 2017, 7, e603-e603.	2.8	161
408	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in theÂpre-brentuximab vedotin era: A LYSA/SFGM-TC study. <i>European Journal of Cancer</i> , 2017, 83, 146-153.	1.3	18
409	Primary gastrointestinal anaplastic large cell lymphoma. <i>Pathology</i> , 2017, 49, 479-485.	0.3	9
410	Application of Immunohistochemistry in Undifferentiated Neoplasms: A Practical Approach. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1014-1032.	1.2	20
411	ALK-positive Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 25-38.	2.1	64
412	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
413	Non-Hodgkin lymphoma of multiple extranodal involvement seen on MRI, FDG PETâ€CT scans. <i>Medicine (United States)</i> , 2017, 96, e8456.	0.4	2
415	Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. <i>Current Treatment Options in Oncology</i> , 2017, 18, 45.	1.3	35
416	Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. <i>Leukemia</i> , 2017, 31, 522-526.	3.3	13
417	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
418	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20â€year British Columbia Cancer Agency experience. <i>British Journal of Haematology</i> , 2017, 176, 234-240.	1.2	20
419	T-cell lymphomas, a challenging disease: types, treatments, and future. <i>International Journal of Clinical Oncology</i> , 2017, 22, 18-51.	1.0	28
420	CD38, BCLâ€2, PDâ€1, and PDâ€1 L expression in nodal peripheral Tâ€cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017, 92, E1-E2.	2.0	33
421	Hematopoietic cell transplants for Hodgkin lymphoma. , 0, , 361-371.		0
422	Hematopoietic cell transplants for T-cell lymphomas. , 0, , 428-435.		0

#	ARTICLE	IF	CITATIONS
423	Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. <i>Blood Advances</i> , 2017, 1, 1945-1958.	2.5	25
424	Brentuximab vedotin: clinical updates and practical guidance. <i>Blood Research</i> , 2017, 52, 243.	0.5	36
425	Anaplastic Lymphoma Kinase in Cutaneous Malignancies. <i>Cancers</i> , 2017, 9, 123.	1.7	7
426	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. <i>Blood Research</i> , 2017, 52, 270.	0.5	6
427	T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. <i>Korean Journal of Radiology</i> , 2017, 18, 71.	1.5	14
428	Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy. <i>European Journal of Dermatology</i> , 2017, 27, 671-673.	0.3	2
429	Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. <i>Gland Surgery</i> , 2017, 6, 169-184.	0.5	83
430	Cutaneous Anaplastic Large T-Cell Lymphoma with Invasion of the Central Nervous System: A Case Report. <i>Brain Tumor Research and Treatment</i> , 2017, 5, 45.	0.4	3
431	ALCL: is it now a curable disease?. <i>Blood</i> , 2017, 130, 2691-2692.	0.6	4
432	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50
433	An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive. <i>Cancers</i> , 2017, 9, 141.	1.7	4
434	Update on the Treatment of Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 135-141.	1.2	20
435	Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2018, 23, 1039-1053.	1.9	41
436	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018, 5, e190-e200.	2.2	50
437	Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the <sc>US</sc> National Cancer Database. <i>British Journal of Haematology</i> , 2018, 181, 196-204.	1.2	15
438	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	2.0	75
439	Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. <i>Annals of Hematology</i> , 2018, 97, 725-726.	0.8	2
440	Immunology of the Lymphomas. , 2018, , 827-852.		1



#	ARTICLE	IF	CITATIONS
441	<scp>ALK</scp>-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. <i>International Journal of Dermatology</i> , 2018, 57, 515-520.	0.5	18
442	ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. <i>Annals of Hematology</i> , 2018, 97, 149-159.	0.8	3
443	A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas. <i>International Journal of Hematology</i> , 2018, 107, 451-459.	0.7	8
444	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
445	<i>Molecular Hematopathology</i> , 2018, , 712-760.e18.		4
446	Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation. <i>Medicine (United States)</i> , 2018, 97, e11222.	0.4	0
447	Orbital T-cell lymphoma in youngest recorded patient – early diagnosis, management, and successful outcome: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2018, 12, 139.	0.4	1
448	Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review). <i>Oncology Letters</i> , 2019, 17, 2020-2030.	0.8	33
449	Prognostic Value of Leukocytosis in Systemic Anaplastic Large-Cell Lymphoma with Cutaneous Involvement. <i>Annals of Dermatology</i> , 2018, 30, 721.	0.3	1
450	PD-L1/PD-1 Check Point in Anaplastic Large Cell Lymphoma, ALK+: A Case Report with Immunohistochemical and Molecular Study. <i>Journal of Cancer Diagnosis</i> , 2018, 03, .	0.1	0
451	Lymphoma in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 285-300.	1.0	7
452	Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 164-175.	2.3	26
453	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97
454	Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 516-524.	1.2	34
455	Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. <i>Journal of Hematology and Oncology</i> , 2018, 11, 75.	6.9	18
456	<i>Cutaneous Lymphomas</i> , 2018, , 769-780.		0
457	Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 318-328.	1.2	18
458	Primary Pulmonary Anaplastic Large Cell Lymphoma: A Rare Malignancy and Rare Cause of the Luftsichel Sign. <i>Case Reports in Radiology</i> , 2018, 2018, 1-5.	0.5	3

#	ARTICLE	IF	CITATIONS
459	Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4583-4590.	1.0	30
460	The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). <i>Cancers</i> , 2018, 10, 107.	1.7	50
461	NHL in adolescents and young adults: A unique population. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27073.	0.8	19
462	Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. <i>Advances in Therapy</i> , 2019, 36, 2679-2696.	1.3	4
464	Recent Advances in Cutaneous T-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 783-803.	0.7	12
465	Pediatric mediastinal ALK- negative anaplastic large cell lymphoma (Hodgkin-like pattern) in a 13-year-old girl: a case report and review of literature. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz077.	0.2	1
466	<i>DUSP22-IRF4</i> rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. <i>BMJ Case Reports</i> , 2019, 12, e230641.	0.2	2
467	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	0.6	9
468	A Supraclavicular ALK-Positive Anaplastic Large-Cell Lymphoma Initially Misdiagnosed and Yet Successfully Treated with Wide Excision and Adjuvant Chemotherapy: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 716-725.	0.3	2
469	nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified. <i>Oncology Letters</i> , 2019, 18, 3803-3810.	0.8	4
470	Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e595-e596.	0.2	8
471	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	2.0	106
472	JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). <i>International Journal of Hematology</i> , 2019, 109, 137-140.	0.7	7
473	Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1942-1949.	0.6	4
474	Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 5209-5220.	0.9	14
475	Anaplastic Large T-Cell Lymphoma in the Intestine of Dogs. <i>Veterinary Pathology</i> , 2019, 56, 878-884.	0.8	7
476	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <i>Histopathology</i> , 2019, 75, 787-796.	1.6	45
477	Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019, 94, 929-946.	2.0	45

#	ARTICLE	IF	CITATIONS
478	Prognostic Factors in Childhood and Adolescent Non-Hodgkin Lymphoma. , 2019, , 131-149.		2
479	High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e337-e342.	0.2	3
480	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019, 104, e562-e565.	1.7	38
481	Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adultâ€”Report of a Rare Case. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 469-476.	0.7	5
482	Anaplastic Large Cell Lymphoma in Children and Adolescents. , 2019, , 251-262.		0
483	FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2019, 24, e180-e187.	1.9	49
484	Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 163-174.	1.4	18
485	Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. <i>Cancer Letters</i> , 2019, 448, 84-93.	3.2	11
486	Anaplastic Large Cell Lymphoma. , 0, , .		1
487	CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation. <i>Blood Advances</i> , 2019, 3, 1788-1794.	2.5	5
488	The prognostic role of 18F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2019, 10, 5805-5811.	1.2	4
489	Clear Cell Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>American Journal of Dermatopathology</i> , 2019, 41, e111-e115.	0.3	3
490	Diffuse Primary Cutaneous Anaplastic Large Cell Lymphoma Treated by Rotational Total Skin Electron Beam Radiotherapy with Custom Shielding: Case Report. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, 454-459.	0.2	1
491	Molecular Drivers of Breast Implantâ€™Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 59S-64S.	0.7	28
492	Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALKâ€™positive anaplastic largeâ€™cell lymphoma refractory to chemotherapy and brentuximab vedotin. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2500-2504.	0.2	6
493	Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. <i>Modern Pathology</i> , 2019, 32, 216-230.	2.9	50
494	A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 904-911.	0.6	8
495	T-Cell and NK-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	0

#	ARTICLE	IF	CITATIONS
496	Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. <i>Cancer Treatment and Research</i> , 2019, 176, 127-144.	0.2	27
497	CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. <i>Haematologica</i> , 2019, 104, 226-235.	1.7	38
498	Moving to a higher echelon in CD30-positive T-cell lymphoma. <i>Lancet, The</i> , 2019, 393, 201-202.	6.3	3
499	Brentuximab vedotin in T-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 5-19.	1.0	18
500	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
501	Anaplastic large cell lymphoma of the palate: A case report. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2019, 120, 172-175.	0.5	2
502	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	2.9	31
503	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 796-803.	1.3	9
504	ALCL by any other name: the many facets of anaplastic large cell lymphoma. <i>Pathology</i> , 2020, 52, 100-110.	0.3	22
505	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 633-640.	1.3	5
506	Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. <i>Annals of Pharmacotherapy</i> , 2020, 54, 371-379.	0.9	21
508	18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma. <i>Cancer Imaging</i> , 2020, 20, 4.	1.2	3
509	Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 431-437.e2.	0.2	3
510	Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. <i>American Journal of Surgical Pathology</i> , 2020, 44, e1-e14.	2.1	13
511	Approach to nodal-based T-cell lymphomas. <i>Pathology</i> , 2020, 52, 78-99.	0.3	18
512	Breast implant-associated anaplastic large cell lymphoma and effusions: A review with emphasis on the role of cytopathology. <i>Cancer Cytopathology</i> , 2020, 128, 440-451.	1.4	14
513	PD-L1 expression in anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 1232-1233.	2.9	2
514	Strategies for aggressive T-cell lymphoma: divide and conquer. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 154-159.	0.9	6

#	ARTICLE	IF	CITATIONS
515	Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. <i>Blood</i> , 2020, 135, 769-773.	0.6	9
516	Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 730.	1.3	2
517	Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine. <i>Frontiers in Oncology</i> , 2020, 10, 898.	1.3	15
518	Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <i>RUNX3</i> overexpression. <i>Hematology Reports</i> , 2020, 12, 8368.	0.3	3
519	Recurrent systemic anaplastic large cell lymphoma: Rapid onset and resolution of cutaneous metastases. <i>JAAD Case Reports</i> , 2020, 6, 124-127.	0.4	1
520	Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1_0,784314_2rgBT /O	1.0	1
521	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK <sup>+</sup> anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020, 34, 2964-2980.	3.3	13
522	Challenges and limitations in the primary diagnosis of T <sub>H</sub> cell and natural killer cell/T <sub>H</sub> cell lymphoma in bone marrow biopsy. <i>Histopathology</i> , 2020, 77, 2-17.	1.6	1
523	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9.	1.1	9
524	Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation. <i>Case Reports in Hematology</i> , 2020, 2020, 1-6.	0.3	0
525	Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 577-583.	1.0	5
526	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
527	Clinical and pathological characteristics of peripheral T <sub>H</sub> cell lymphomas in a Spanish population: a retrospective study. <i>British Journal of Haematology</i> , 2021, 192, 82-99.	1.2	5
528	Anaplastic large cell lymphoma in human immunodeficiency virus-infected people and solid organ transplant recipients. <i>British Journal of Haematology</i> , 2021, 192, 514-521.	1.2	2
529	Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e1-e9.	0.2	5
530	A review of <i>CD30</i> expression in cutaneous neoplasms. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 495-510.	0.7	12
531	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2021, 35, 1500-1505.	3.3	29
532	Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. <i>British Journal of Haematology</i> , 2021, 192, e17-e21.	1.2	2

#	ARTICLE	IF	CITATIONS
533	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	1.1	6
534	Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?. <i>Leukemia and Lymphoma</i> , 2021, 62, 538-548.	0.6	3
535	Indolent and Aggressive Mature T-Cell and Natural Killerâ€“Cell Lymphomas. , 2021, , 251-273.		0
536	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. <i>Annals of Translational Medicine</i> , 2021, 9, 128-128.	0.7	2
541	Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1203-1215.	0.9	6
542	Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Frontiers in Oncology</i> , 2021, 11, 607145.	1.3	6
544	Leukaemic relapse of anaplastic large cell lymphoma, ALK negative. <i>BMJ Case Reports</i> , 2021, 14, e239213.	0.2	3
547	ALK-negative primary cutaneous T-cell anaplastic large cell lymphoma, myxoid variant; masquerading as sarcoma: unveiling the diagnostic dilemma. <i>BMJ Case Reports</i> , 2021, 14, e239350.	0.2	2
548	Acquired ichthyosis and false-positive hepatitis A serology as paraneoplastic phenomena in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. <i>BMJ Case Reports</i> , 2021, 14, e240966.	0.2	1
549	Successful treatment of post chemotherapy esophageal cicatricial atresia in a pediatric patient with anaplastic large cell lymphoma through minimally invasive esophagectomy: a case report. <i>Surgical Case Reports</i> , 2021, 7, 41.	0.2	0
550	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. <i>American Journal of Surgical Pathology</i> , 2021, 45, 895-904.	2.1	29
551	Conditional survival and hazards of death for peripheral T-cell lymphomas. <i>Aging</i> , 2021, 13, 10225-10239.	1.4	6
552	How I Diagnose Anaplastic Large Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2021, 155, 479-497.	0.4	20
553	Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.3	1
554	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. <i>Blood Cancer Journal</i> , 2021, 11, 56.	2.8	3
555	AGENT ORANGEâ€“INDUCED Anaplastic Largeâ€“Cell Lymphoma (ALCL) with Cutaneous Involvement. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2373-2381.	0.2	1
557	Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. <i>Seminars in Hematology</i> , 2021, 58, 85-94.	1.8	4
558	Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors. <i>Medicine (United States)</i> , 2021, 100, e25576.	0.4	2

#	ARTICLE	IF	CITATIONS
559	Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. <i>Medicine (United States)</i> , 2021, 100, e25194.	0.4	6
560	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. <i>Advances in Therapy</i> , 2021, 38, 3789-3802.	1.3	3
561	Targeted Approaches to T-Cell Lymphoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 481.	1.1	1
562	Primary anaplastic large cell lymphoma of the CNS as initial presentation of HIV infection: A case report. <i>Human Pathology: Case Reports</i> , 2021, 24, 200513.	0.2	3
563	Aggressive Tâ€cell lymphomas: 2021 Updates on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2021, 96, 1027-1046.	2.0	20
564	Rapidly progressing primary pulmonary lymphoma masquerading as lung infectious disease: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 4016-4023.	0.3	0
565	The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2021, 14, 777-787.	1.0	17
567	Sinonasal Lymphoma: Extranodal Natural Killer/T-Cell Lymphoma and Its Differential Diagnosis. <i>AJSP Review and Reports</i> , 2021, 26, 226-239.	0.0	0
568	Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 867-875.	1.0	11
569	Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , 2021, 13, 4256.	1.7	1
570	Diagnosis of anaplastic lymphoma kinaseâ€negative anaplastic large cell lymphoma on pleural fluid cytology. <i>Diagnostic Cytopathology</i> , 2021, 49, E458-E461.	0.5	1
571	Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma: Diagnostic Perils and Pitfalls, an Underrecognized Entity. <i>Cureus</i> , 2021, 13, e16882.	0.2	0
572	Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study. <i>Cancer Research and Treatment</i> , 2022, 54, 613-620.	1.3	2
573	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. <i>Modern Pathology</i> , 2022, 35, 306-318.	2.9	16
574	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. <i>JAAD Case Reports</i> , 2021, 17, 34-37.	0.4	1
575	ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas. <i>Cancers</i> , 2021, 13, 4667.	1.7	20
576	Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990â€2019: Results From the Global Burden of Disease Study 2019. <i>Frontiers in Medicine</i> , 2021, 8, 738693.	1.2	20
577	T time: Emerging and new therapies for peripheral T-cell lymphoma. <i>Blood Reviews</i> , 2022, 52, 100889.	2.8	6

#	ARTICLE	IF	CITATIONS
578	Lymph Nodes. , 2022, , 763-813.		0
579	Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case. Head and Neck Pathology, 2021, 15, 1335-1344.	1.3	2
580	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Advances, 2021, 5, 640-648.	2.5	22
581	The DNA-helicase HELLS drives ALK <sup>+</sup> ALCL proliferation by the transcriptional control of a cytokinesis-related program. Cell Death and Disease, 2021, 12, 130.	2.7	10
582	Title is missing!. , 2017, , .		1
583	Anaplastic Large Cell Lymphoma, ALK Positive and ALK Negative. , 2011, , 564-579.		1
586	Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthetic Surgery Journal, 2019, 39, S14-S20.	0.9	27
587	Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2020, 44, 776-781.	2.1	25
588	Anaplastic Large Cell Lymphoma: Emerging Consent and Management Patterns among American and International Board Certified Plastic Surgeons. Plastic and Reconstructive Surgery, 2016, 138, 811e-818e.	0.7	16
589	Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. Journal of Clinical Investigation, 2015, 125, 3505-3518.	3.9	32
590	Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas. Hematology American Society of Hematology Education Program, 2008, 2008, 272-279.	0.9	8
591	The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology American Society of Hematology Education Program, 2009, 2009, 523-531.	0.9	57
592	Biomarker-driven management strategies for peripheral T cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 59.	6.9	26
593	Recent advances in understanding and managing T-cell lymphoma. F1000Research, 2017, 6, 2123.	0.8	4
594	Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Research, 2020, 9, 1091.	0.8	8
595	Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma masquerading as Behcet's disease: A case report and review of literature. World Journal of Clinical Cases, 2019, 7, 3377-3383.	0.3	3
596	Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas. PLoS ONE, 2015, 10, e0121822.	1.1	9
597	The heterogeneous landscape of ALK negative ALCL. Oncotarget, 2017, 8, 18525-18536.	0.8	28



#	ARTICLE	IF	CITATIONS
598	Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. <i>Journal of Clinical and Experimental Hematopathology</i> : JCEH, 2017, 57, 120-142.	0.3	72
599	Anaplastic lymphoma kinase-positive large cell lymphoma of the anterior skull base: Report of an unusual case and review of the literature. , 2013, 4, 57.		8
600	Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile. <i>South Asian Journal of Cancer</i> , 2017, 06, 129-131.	0.2	5
601	Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL. <i>Indian Journal of Cancer</i> , 2020, 58, 108-111.	0.2	1
602	Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. <i>Cancer Research and Treatment</i> , 2018, 50, 599-613.	1.3	9
603	Anaplastic Large Cell Lymphoma, ALK-Negative Presenting in the Rectum: A Case Report and Review of the Literature. <i>Open Journal of Pathology</i> , 2013, 03, 37-40.	0.0	3
604	The Current Lymphoma Classification: New Concepts and Practical Applications“Triumphs and Woes. <i>Annals of Saudi Medicine</i> , 2012, 32, 296-305.	0.5	6
605	Research progresses in the pathogenesis of anaplastic large cell lymphoma. <i>Chinese Journal of Cancer</i> , 2011, 30, 392-399.	4.9	2
606	Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 49-56.	1.2	47
607	Anaplastic Large Cell Lymphoma: Twenty-Five Years of Discovery. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 19-43.	1.2	98
608	Nodal and extranodal peripheral T/NK-cell neoplasms: Current aspects. <i>Acta Facultatis Medicae Naissensis</i> , 2020, 37, 99-120.	0.1	2
609	Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, .	0.2	27
610	A Case Study of Soeumin with Peripheral T-cell Lymphoma who Showed Symptomatic Improvement including Fever, Myalgia, Performance Status, and Headache after Treated with Osuyubujaijung-tang and Geopoong-san. <i>Journal of Sasang Constitutional Medicine</i> , 2012, 24, 100-108.	0.1	6
611	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2022, 35, 412-418.	2.9	4
612	Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data. <i>British Journal of Haematology</i> , 2022, 196, 932-938.	1.2	2
613	Co-occurring rearrangements of <i>DUSP22</i> and <i>TP63</i> define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 506-508.	0.6	7
614	Lymphomes T pŃ©riphŃ©riques. , 2010, , 91-97.		0
615	Hodgkin Disease and Non-Hodgkin Lymphomas. , 2010, , 571-639.		0

#	ARTICLE	IF	CITATIONS
622	Misleading Features of Bone Marrow Involvement by Peripheral T-Cell Lymphomas. , 2012, , 253-270.		1
623	A Case of Anaplastic Lymphoma Kinase-Negative Primary Gastric Anaplastic Large Cell Lymphoma. Korean Journal of Medicine, 2012, 83, 674.	0.1	1
624	A Case of Primary Gastric ALK-Positive Anaplastic Large-Cell Lymphoma. Korean Journal of Medicine, 2012, 83, 752.	0.1	0
625	Childhood Lymphoma. , 2012, , 101-124.		0
626	Molecular Diagnosis in Hematopathology. , 2012, , 679-726.		1
627	Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Journal of the Advanced Practitioner in Oncology, 2012, 3, 184-90.	0.2	2
628	Molecular Profiling and Prognosis in T-Cell Lymphomas. , 2013, , 41-56.		0
629	Histopathology and Classification of T-Cell Lymphomas. , 2013, , 1-24.		0
631	Primary Cutaneous and Systemic CD30+ T-cell Lymphoproliferative Disorders. , 2013, , 71-86.		0
632	Malignant Lymphomas Involving Lung and Pleura. , 2013, , 319-347.		0
633	Prognostic Factors in Peripheral T-Cell Lymphomas. , 2013, , 141-152.		0
634	The Effectiveness of Combined Medical Therapy and Hemodialysis for Hypercalcemia in Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma. The Showa University Journal of Medical Sciences, 2013, 25, 233-241.	0.1	0
635	Primary Anaplastic Large Cell Lymphoma of the Nasal Cavity: A Case Report. International Journal of Clinical Medicine, 2013, 04, 195-199.	0.1	2
636	Anaplastic large cell lymphoma ALK-negative clinically mimicking alcoholic hepatitisÂ review. Autopsy and Case Reports, 2013, 3, 11-19.	0.2	1
637	T-Cell Lymphomas. , 2013, , 211-229.		0
638	Lymphomes cutanÃ©s secondaires. , 2013, , 205-223.		1
639	Lymphomas. , 2013, , 962-974.		0
640	Molecular Profiling of Peripheral T-Cell Lymphomas. , 2013, , 53-63.		0

#	ARTICLE	IF	CITATIONS
641	Traitements des lymphomes T pÃ©riphÃ©riques. , 2013, , 137-150.		0
643	A Case of Anaplastic Large Cell Lymphoma (ALCL) Associated with Atopic Dermatitis. Nishinon Journal of Dermatology, 2014, 76, 109-114.	0.0	0
644	Anaplastic Large Cell Lymphoma. , 2014, , 111-120.		0
645	Rare Presentation of Large Cell Lymphoma. MGM Journal of Medical Sciences, 2014, 1, 41-43.	0.1	0
646	Signaling Pathways in Rare Lymphomas. , 2014, , 71-95.		0
652	Anaplastic Large Cell Lymphoma in Children and Adolescents. , 2016, , 357-362.		0
653	A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Journal of Health Economics and Outcomes Research, 2016, 4, 188-203.	0.6	1
654	Non-Hodgkinâ€™s Lymphomas in Children: 25-Year Clinical Experience. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 420-437.	0.1	5
655	Systemic T-cell lymphoma. , 2017, , 173-201.		0
656	Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia. In Vivo, 2017, 31, 701-704.	0.6	2
657	Anaplastic Large Cell Lymphoma in Blood and Bone Marrow. , 2018, , 866-871.		0
658	Anaplastic Large Cell Lymphoma, ALK(+). , 2018, , 722-729.		0
659	ALK(+) Anaplastic Large Cell Lymphoma. , 2018, , 370-371.		0
660	Mediastinal Anaplastic Large-Cell Lymphoma. Encyclopedia of Pathology, 2018, , 200-210.	0.0	0
661	PD-1/PD-L1 Checkpoint in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report. Biomedical Journal of Scientific & Technical Research, 2018, 3, .	0.0	3
662	Aggressive Lymphoma. , 2019, , 387-399.		0
663	Pathology and Molecular Pathogenesis of T-Cell Lymphoma. Springer Reference Medizin, 2019, , 95-141.	0.0	1
664	Standard of Care in T-Cell Lymphoma. Essentials, 2019, , 227-244.	0.1	0

#	ARTICLE	IF	CITATIONS
665	The usefulness of straight chemotherapy for dermal exposed anaplastic lymphoma kinase fusion-positive anaplastic large-cell lymphoma with intracranial invasion. Journal of Innovative Optical Health Sciences, 2019, 14, 1218-1221.	0.5	1
666	Anaplastic Large Cell Lymphoma of the Duodenum in a Teenage Girl: Misdiagnosed as an Intramural Duodenal Hematoma. Pediatric Gastroenterology, Hepatology and Nutrition, 2019, 22, 571.	0.4	2
667	ALK Positive Anaplastic Large Cell Lymphoma of Oral Cavity: A Case Report. International Journal of Cancer Management, 2019, In Press, .	0.2	0
668	A Case of Peripheral T Cell Lymphoma in a Patient with Psoriasis Vulgaris. Nishinohon Journal of Dermatology, 2019, 81, 22-25.	0.0	0
669	Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	0
670	Linfomas no Hodgkin: actitud terapéutica. EMC - Tratado De Medicina, 2019, 23, 1-7.	0.0	0
671	ALK-Negative Anaplastic Large-Cell Lymphoma Diagnosed on Liver Biopsy in a Child Presenting with Nonresolving Pyrexia. Indian Journal of Medical and Paediatric Oncology, 2019, 40, S169-S172.	0.1	0
672	Lymphomas. , 2020, , 253-315.		0
673	Stage IV Breast Implant-associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy. Plastic and Reconstructive Surgery - Global Open, 2019, 7, e2446.	0.3	8
674	Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas. , 2020, , 27-46.		0
675	The Hematopathology and Diagnostic Challenges of Rare Lymphomas. , 2020, , 1-13.		0
676	Anaplastic Large Cell Lymphoma. , 2020, , 179-189.		0
677	Anaplastic Large Cell Lymphoma ALK-Negative: About a Rare Pediatric Case Report. The Open Pediatric Medicine Journal, 2020, 10, 3-5.	1.6	0
678	Intermediate Results of Prospective, Randomized, Comparative Study of NHL BFM-90 and Đ;ĐĐžĐ•Đ Efficacy in Primary ALK-Positive Anaplastic LargeCell Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 382-388.	0.1	0
679	A Severe Case of Anaplastic Large Cell Lymphoma in a Previously Healthy Woman: Diagnostic and Therapeutic Challenges. Prague Medical Report, 2020, 121, 262-266.	0.4	1
680	Low-dose Methotrexate Treatment for Solitary or Localized Primary Cutaneous Anaplastic Large Cell Lymphoma: A Long-term Follow-up Study. Acta Dermato-Venereologica, 2020, 100, adv00069.	0.6	2
681	Major Subtypes of Mature T- and NK-Cell Neoplasms. , 2020, , 175-188.		0
682	Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 2021, , .	0.5	1

#	ARTICLE	IF	CITATIONS
683	Acute leukemic phase of anaplastic lymphoma kinase-anaplastic large cell lymphoma: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2020, 8, 5439-5445.	0.3	0
684	Lymph nodes and spleen. , 2015, , 688-812.		1
685	Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. <i>International Journal of Clinical and Experimental Pathology</i> , 2009, 2, 508-18.	0.5	10
686	Pitfalls in diagnostic hematopathology – Part II. <i>International Journal of Clinical and Experimental Pathology</i> , 2009, 3, 39-46.	0.5	8
687	Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality?. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 4, 100-10.	0.5	10
688	ALK-immunoreactive neoplasms. <i>International JKL of Clinical and Experimental Pathology</i> , 2012, 5, 397-410.	0.5	31
689	Pericardial involvement as an initial presentation of anaplastic large cell lymphoma. <i>Canadian Family Physician</i> , 2014, 60, 638-41.	0.1	5
690	Sarcomatoid variant of ALK- anaplastic large cell lymphoma involving multiple lymph nodes and both lungs with production of proinflammatory cytokines: report of a case and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4806-16.	0.5	7
691	Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, 22-36.	0.2	35
693	Pediatric anaplastic large cell lymphoma misdiagnosed as multiple organ abscesses: a case report and literature review. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 19509-16.	1.3	2
694	PAX-5 positive anaplastic large cell lymphoma presenting by dysphagia; a case report. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2017, 10, 332-336.	0.6	1
697	Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches. <i>Cancers</i> , 2021, 13, 5774.	1.7	9
698	The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. <i>Advances in Therapy</i> , 2022, 39, 532-543.	1.3	5
699	Guidelines for the management of mature T&and natural killer&cell lymphomas (excluding cutaneous) Tj ETQq1 1 0.784314 rgBT /Ov 196, 507-522.	1.2	12
700	Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2022, 101, 789.	0.8	0
701	What are the likely causes of breast implant associated anaplastic large cell lymphoma (BIA-ALCL)?. <i>JPRAS Open</i> , 2022, 32, 34-42.	0.4	18
702	Safety considerations with the current treatments for peripheral T-cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 653-660.	1.0	1
703	ALK-positive anaplastic large cell lymphoma of skeletal muscle masquerading as soft tissue sarcoma. <i>BMJ Case Reports</i> , 2022, 15, e245685.	0.2	4

#	ARTICLE	IF	CITATIONS
704	The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2022, 33, 288-298.	0.6	99
705	Anaplastic large cell lymphoma, ALK-negative of the breast diagnosed a short time after removal of breast implant in a patient with breast carcinoma: diagnostic and therapeutic considerations. <i>BMJ Case Reports</i> , 2022, 15, e248232.	0.2	0
706	Anaplastic Large Cell Lymphoma Presenting as Ulcerative Facial Mass: A Case Report. <i>Case Reports in Oncology</i> , 2022, 15, 199-206.	0.3	0
707	T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 285-308.	2.3	58
708	CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 415-432.	1.2	2
709	Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment. <i>Cancers</i> , 2022, 14, 1650.	1.7	18
710	Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma. <i>Cureus</i> , 2022, 14, e23627.	0.2	0
711	Primary Cutaneous Anaplastic Large Cell Lymphoma of the Nasal Dorsum and Nasal Tip. <i>Cureus</i> , 2022, 14, e23811.	0.2	0
712	BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. <i>Cancers</i> , 2022, 14, 151.	1.7	2
713	Bone marrow. , 0, , 813-942.		0
714	WHO classification of lymphomas. , 0, , 228-256.		0
715	Peripheral T-cell lymphomas. , 0, , 410-431.		0
716	LYMPHOID, MYELOID, HISTIOCYTIC, AND DENDRITIC CELL PROLIFERATIONS IN SOFT TISSUES. , 0, , 982-1015.		0
718	Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. <i>Blood Advances</i> , 2022, 6, 5550-5555.	2.5	17
720	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 79-86.	1.2	1
721	Peripheral T-Cell Lymphomas: Therapeutic Approaches. <i>Cancers</i> , 2022, 14, 2332.	1.7	4
722	Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage. <i>Annals of Translational Medicine</i> , 2022, 10, 570-570.	0.7	3
723	Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2022, 12, 964.	1.1	1

#	ARTICLE	IF	CITATIONS
724	A challenging case of ALK-negative anaplastic large cell lymphoma in a 12-year-old boy: A rare case report from Syria. <i>Annals of Medicine and Surgery</i> , 2022, 79, 104085.	0.5	0
725	Hodgkin Lymphoma: Biology and Differential Diagnostic Problem. <i>Diagnostics</i> , 2022, 12, 1507.	1.3	2
726	Up-front therapy with CHOP plus etoposide in Brazilian nodal PTCL patients: increased toxicity and no survival benefit compared to CHOP regimen – results of a real-life study from a middle-income country. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
727	Left Forearm Langerhans Cell Sarcoma Demonstrated by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
728	The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	3
729	Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas. <i>Diagnostics</i> , 2022, 12, 2001.	1.3	5
730	Management of Peripheral T-cell Lymphomas and the Role of Transplant. <i>Current Oncology Reports</i> , 2022, 24, 1489-1499.	1.8	4
731	Immunohistochemical Approach to Genetic Subtyping of Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1490-1499.	2.1	10
732	Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2023, 200, 54-63.	1.2	2
733	Metastatic anaplastic large cell lymphoma of the omentum presenting as an ulcerated nodule on the back. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 0, , .	0.2	0
734	A Case of Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma of Sphenoid Sinus. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2023, 66, 692-696.	0.0	0
735	Anaplastic large cell lymphoma, ALK-negative exhibiting rare CD4 [â€%+] CD8 [â€%+] double-positive immunophenotype. <i>Journal of Hematopathology</i> , 0, , .	0.2	0
736	JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK <sup>-</sup> Anaplastic Large Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2023, 47, 55-64.	2.1	4
738	Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
739	Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 0, , .	0.7	0
740	&lt;i>&gt;DUSP22&lt;/i>-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome. <i>Haematologica</i> , 2023, 108, 1463-1467.	1.7	6
741	ALK-negative anaplastic large cell lymphoma with &lt;i>&gt;DUSP22&lt;/i> rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study. <i>Haematologica</i> , 2023, 108, 1590-1603.	1.7	10
742	Mature T-cell and NK-cell lymphomas: updates on molecular genetic features. <i>International Journal of Hematology</i> , 2023, 117, 475-491.	0.7	2

#	ARTICLE	IF	CITATIONS
743	Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK+ anaplastic large cell lymphoma. <i>Journal of Hematopathology</i> , 0, , .	0.2	0
744	The Standard of Care in Relapsed Refractory CD30+ Lymphoma. <i>European Medical Journal Hematology</i> , 0, , 62-69.	0.0	0
745	The plasticity of biocompatibility. <i>Biomaterials</i> , 2023, 296, 122077.	5.7	6
746	Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101444.	0.7	6
747	Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability. <i>Blood Advances</i> , 2023, 7, 4049-4063.	2.5	3
748	Nomograms for predicting overall survival and cancer-specific survival in patients with head and neck non-Hodgkin lymphoma: A population-based study. <i>Medicine (United States)</i> , 2023, 102, e32865.	0.4	0
749	Current and Future Developments in the Treatment of CD30+ Lymphomas. <i>European Medical Journal Oncology</i> , 0, , 87-93.	0.0	0
750	Haemophagocytic Lymphohistiocytosis Associated With Anaplastic Large-Cell Lymphoma in a Young Woman. <i>Cureus</i> , 2023, , .	0.2	1
751	Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2023, 29, 314-323.	0.5	0
752	Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. <i>Oncologist</i> , 0, , .	1.9	2
753	A 12-year-old male with localized, pink, tender papules. <i>Pediatric Dermatology</i> , 2023, 40, 367-368.	0.5	0
754	First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology. <i>Current Oncology Reports</i> , 0, , .	1.8	0
768	Lymphoid, myeloid, histiocytic, and dendritic cell proliferations in soft tissues. , 2016, , 941-974.		0
771	Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
775	Anaplastic large cell lymphoma presenting as a mass in the uterine cervix: a case report. <i>Journal of Hematopathology</i> , 2024, 17, 23-26.	0.2	0